Dataset Information

Phenotypic signature of USPl7L2

ABSTRACT: The deubiquitinase USP17 was previously shown to regulate KLF4 expression in hepatocellular carcinomas. The KLF4 transcription factor is a major regulator of the phenotypic response of vascular smooth muscle cells, enabling their polarization toward a synthetic phenotype observed in several aortic remodeling diseases, including aneurysms and atherosclerosis. The aim here was therefore to reduce USP17 expression in primary-cultured human aortic smooth muscle cells and to verify their fate (contractile or synthetic phenotype) through proteomic analysis.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Eric Bonneil

LAB HEAD: Marc Servant

PROVIDER: PXD074824 | Pride | 2026-02-25

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	Service_Servant_3473_170226_1.raw	Raw
	Service_Servant_3473_170226_2.raw	Raw
	Service_Servant_3473_170226_3.raw	Raw
	Service_Servant_3473_170226_4.raw	Raw
	Service_Servant_3473_170226_5.raw	Raw

Items per page:

1 - 5 of 8

Similar Datasets

Project description:BACKGROUND: Vascular smooth muscle cells (vSMCs), the predominant cell type in the aortic wall, play a crucial role in maintaining aortic integrity, blood pressure, and cardiovascular function. vSMC contractility and function depend on smooth muscle alpha-actin 2 (ACTA2). The pathogenic variant ACTA2 c.536G>A (p. R179H) causes multisystemic smooth muscle dysfunction syndrome (MSMDS), a severe disorder marked by widespread smooth muscle abnormalities, resulting in life-threatening aortic disease and high risk early mortality from aneurysms or stroke. No effective treatments exist for MSMDS. METHODS: To develop a comprehensive therapy for MSMDS, we utilized CRISPR-Cas9 adenine base editing to correct the ACTA2 R179H mutation. We generated isogenic human induced pluripotent stem cell (iPSC) lines and humanized mice carrying this pathogenic missense mutation. iPSC-SMCs were evaluated for key functional characteristics, including proliferation, migration, and contractility. The adenine base editor (ABE) ABE8e-SpCas9-VRQR under control of either a SMC-specific promoter or a CMV promoter, and an optimized single guide RNA (sgRNA) under control of U6 promoter were delivered intravenously to humanized R179H mice using adeno-associated virus serotype 9 (AAV9) and phenotypic outcomes were evaluated. RESULTS: The R179H mutation causes a dramatic phenotypic switch in human iPSC-SMCs from a contractile to a synthetic state, a transition associated with aneurysm formation. Base editing prevented this pathogenic phenotypic switch and restored normal SMC function. In humanized mice, the ACTA2R179H/+ mutation caused widespread smooth muscle dysfunction, manifesting as decreased blood pressure, aortic dilation and dissection, bladder enlargement, gut dilation, and hydronephrosis. In vivo base editing rescued these pathological abnormalities, normalizing smooth muscle function. CONCLUSIONS: This study demonstrates the effectiveness of adenine base editing to treat MSMDS and restore aortic smooth muscle function. By correcting the ACTA2 R179H mutation, the pathogenic phenotypic shift in SMCs was prevented, key aortic smooth muscle functions were restored, and life-threatening aortic dilation and dissection were mitigated in humanized mice. These findings underscore the promise of gene-editing therapies in addressing the underlying genetic causes of smooth muscle disorders and offer a potential transformative treatment for patients facing severe vascular complications.

Dataset Information

Phenotypic signature of USPl7L2

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets